By Shashank Upadhye ( September 11, 2026, 5:42 PM EDT) -- The U.S. Court of Appeals for the District of Columbia Circuit's Aug. 18 decision in Vanda Pharmaceuticals v. U.S. Food and Drug Administration presents an unusual Hatch-Waxman Act result: Vanda won the principal statutory interpretation issue, but Teva Pharmaceuticals keeps its generic approval, at least for now....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.